| Literature DB >> 35468926 |
Yutaro Ide1, Bouchra Kitab1, Nobumasa Ito1, Riai Okamoto1, Yui Tamura1, Takafumi Matsui1, Yoshihiro Sakoda2, Kyoko Tsukiyama-Kohara3,4.
Abstract
Foot-and-mouth disease virus (FMDV) and classical swine fever virus (CSFV) possess positive-sense single-stranded RNA genomes and an internal ribosomal entry site (IRES) element within their 5'-untranslated regions. To investigate the common host factors associated with these IRESs, we established cell lines expressing a bicistronic luciferase reporter plasmid containing an FMDV-IRES or CSFV-IRES element between the Renilla and firefly luciferase genes. First, we treated FMDV-IRES cells with the French maritime pine extract, Pycnogenol (PYC), and examined its suppressive effect on FMDV-IRES activity, as PYC has been reported to have antiviral properties. Next, we performed microarray analysis to identify the host factors that modified their expression upon treatment with PYC, and confirmed their function using specific siRNAs. We found that polycystic kidney disease 1-like 3 (PKD1L3) and ubiquitin-specific peptidase 31 (USP31) were associated with FMDV-IRES activity. Moreover, silencing of these factors significantly suppressed CSFV-IRES activity. Thus, PKD1L3 and USP31 are host factors associated with the functions of FMDV- and CSFV-IRES elements.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35468926 PMCID: PMC9039067 DOI: 10.1038/s41598-022-10437-z
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.996
List of siRNAs targeting host factors.
| Name of host factor | siRNA sequence |
|---|---|
| 1. lnc-IFI44-2 | 5’-CCAAUGCUGUGAGAGUUGUACAUGU-3’ |
| 2. PKD1L3 | 5′- CAGUUCAUGGUUUGCAAGCUCUUAA-3′, |
| 4. ENST456414 | 5’-GAGGAGGGAAGAGAAUGAATCUUAU-3’ |
| 5. lnc-SGBT-2 | 5’-CAGUGCCCAUGUUUCUUGUGUUUAA-3’ |
| 6. ENST455576 | 5’-UGCAGUGCAUUUGCCUCCCUCACUU-3’ |
| 7. SLC24A4 | 5’-GACGGUAGCUAUGAUGACCCUUCCG-3’ |
| 8. USP31 | 5′- CAGCACAGCCGCGACUUCAAGACUA-3′ |
| 9. ENST554254 | 5’-ACAGGUCAAGUGAAGUUCUUCUGCU-3’ |
| 10. HGF | 5’-GGGACCCUGGTGUUUCACAAGCAAU-3’ |
Figure 1Treatment of FMDV-IRES expressing cells with PYC. (A) FMDV-IRES-expressing B5 and B10 cells were treated with PYC at final concentrations of 0, 10, and 100 μg/mL. After 72 h of incubation, firefly and Renilla luciferase activities were evaluated, and IRES activity was calculated as the ratio of firefly luciferase activity to Renilla luciferase activity, plotted against the value for the untreated sample. + P = 0.022, *P = 0.037, #P = 0.0049 (B) The ratio (%) of the WST value (OD450) versus the untreated sample is shown. FMDV-IRES expressing SK-L cells were treated with PYC and the luciferase activity (C) and WST values (D) were evaluated. Bars and vertical bars indicate the mean values of the triplicate samples and S.D, respectively. P values indicate statistical significance. @P = 0.017. FMDV foot-and-mouth disease virus, IRES internal ribosomal entry site, PYC pycnogenol.
Result of microarray analysis (top 10 downregulated genes by PYC treatment).
| No. | GeneName | SystematicName | Accessions | Chr_coord | Description | FoldChange* | PValueLogRatio | gProcessedSignal | rProcessedSignal |
|---|---|---|---|---|---|---|---|---|---|
| 1 | lnc-IFI44-2 | lnc-IFI44-2:4 | linc|lnc-IFI44-2:4|linc|lnc-IFI44-2:5|linc|lnc-IFI44-2:3|linc|TCONS_00002078 | hs|chr1:79869806-79871942 | linc|LNCipedia lincRNA (lnc-IFI44-2), lincRNA [lnc-IFI44-2:4] | 1.50E+01 | 9.72E−15 | 8.31E+01 | 5.54E+00 |
| 2 | NM_181536 | ref|NM_181536|ens|ENST00000620267|linc|lnc-ZNF821-2:1|linc|lnc-ZNF821-2:2 | hs|chr16:71963542-71963483 | ref|Homo sapiens polycystic kidney disease 1-like 3 (PKD1L3), mRNA [NM_181536] | 1.16E+01 | 8.55E−12 | 6.28E+01 | 5.43E+00 | |
| 3 | LOC100129935 | NR_026870 | ref|NR_026870|ens|ENST00000597791|ens|ENST00000597077|ens|ENST00000594263 | hs|chr19:40131243-40131302 | ref|Homo sapiens lectin, galactoside-binding, soluble, 14 pseudogene (LOC100129935), non-coding RNA [NR_026870] | 6.81E+00 | 9.66E−04 | 2.23E+01 | 3.27E+00 |
| 4 | ENST00000456414 | ENST456414 | ens|ENST00000456414|linc|lnc-CD58-1:1|gb|AL832882|gb|AK126833 | hs|chr1:117035719-117035660 | gb|Homo sapiens mRNA; cDNA DKFZp667K053 (from clone DKFZp667K053). [AL832882] | 5.03E+00 | 7.27E−04 | 2.61E+01 | 5.19E+00 |
| 5 | lnc-SGTB-2 | lnc-SGTB-2:1 | linc|lnc-SGTB-2:1|tc|THC2736569 | hs|chr5:65440279-65440220 | tc|K1C14_MOUSE (Q61781) Keratin, type I cytoskeletal 14 (Cytokeratin-14) (CK-14) (Keratin-14) (K14), partial (5%) [THC2736569] | 4.69E+00 | 2.13E−05 | 3.60E+01 | 7.67E+00 |
| 6 | ENST00000455576 | ENST455576 | ens|ENST00000455576|linc|lnc-RARB-1:1|gb|DA240288 | hs|chr3:25215706-25215765 | gb|DA240288 BRAWH3 Homo sapiens cDNA clone BRAWH3037815 5', mRNA sequence [DA240288] | 4.25E+00 | 3.06E−03 | 2.11E+01 | 4.97E+00 |
| 7 | NM_153646 | ref|NM_153646|ref|NM_153647|ref|NM_153648|ens|ENST00000531433 | hs|chr14:92962507-92962566 | ref|Homo sapiens solute carrier family 24 (sodium/potassium/calcium exchanger), member 4 (SLC24A4), transcript variant 1, mRNA [NM_153646] | 4.19E+00 | 9.53E−04 | 2.57E+01 | 6.13E+00 | |
| 8 | NM_020718 | ref|NM_020718|ens|ENST00000219689|linc|lnc-COG7-2:1|ref|XM_005255450 | hs|chr16:23074153-23074094 | ref|Homo sapiens ubiquitin specific peptidase 31 (USP31), mRNA [NM_020718] | 4.10E+00 | 1.51E−03 | 2.70E+01 | 6.60E+00 | |
| 9 | ENST00000554254 | ENST554254 | ens|ENST00000554254|linc|lnc-TMEM30B-5:1|tc|THC2667238|tc|THC2685569 | hs|chr14:62217662-62217603 | ens|HIF1A antisense RNA 2 [Source:HGNC Symbol;Acc:HGNC:43015] [ENST00000554254] | 4.09E+00 | 2.26E−04 | 3.01E+01 | 7.35E+00 |
| 10 | NM_001010934 | ref|NM_001010934|ens|ENST00000423064|gb|AB208900|gb|U46010 | hs|chr7:81380346-81380287 | ref|Homo sapiens hepatocyte growth factor (hepapoietin A; scatter factor) (HGF), transcript variant 5, mRNA [NM_001010934] | 4.04E+00 | 7.73E−10 | 8.83E+01 | 2.19E+01 |
*Top 10 downregulated genes (fold decrease) by PYC treatment were shown. Gene name, systematic name, accession name etc has been indicated.
Figure 2Transfection of siRNA into FMDV-IRES expressing cells. siRNA targeting nine upregulated genes (Table 1) was reverse transfected into FMDV-IRES-expressing cells B10 (A) and B5 (C). The IRES activity was evaluated as shown in Fig. 1. Statistical analysis was performed using the Student’s t-test to compare the control siRNA-treated cells and cells transfected with siRNA targeting host factors. *P = 0.011, #P = 0.021 (B,D) The ratio (%) of the WST value (OD450) versus untreated sample in B10 (B) and B5 (D) cells. *P = 0.021. Bars and vertical bars indicate the mean values of triplicate samples and SD, respectively.
Figure 3Structure of the bicistronic luciferase reporter construct and response to PYC. (A) A bicistronic reporter construct was designed to contain the CSFV-IRES element located between the Renilla and firefly luciferase genes. The bicistronic reporter gene was excised using the restriction enzymes EcoRV and BamHI and ligated into the pCAGGS-Neo/MCS vector digested with EcoRV and BamHI. (B) CSFV-IRES-expressing cell lines (pCI5 and pCI5-1) were treated with PYC at final concentrations of 0, 10, or 100 μg/mL. After 72 h of incubation, the firefly and Renilla luciferase activities were evaluated, and IRES activity was calculated as the ratio of firefly to Renilla luciferase activity plotted against the value for the untreated sample. *P = 0.016, #P = 0.00061 (C)The ratio (%) of the WST value (OD450) vs. the untreated sample is shown. CSFV-IRES expressing SK-L cells were treated with PYC and the luciferase activity (D) and WST values (E) were evaluated. +P = 0.0021 The mean value for triplicate samples is indicated, and the vertical bars show SD. CSFV, classical swine fever virus.
Figure 4Effect of PYC to CSFV infection. (A) SK-L cells in triplicate wells (6 well plates) were infected with vCSFV GPE−/HiBiT at a multiplicity of infection (MOI) of 0.1, 0.01, and 0.01, treated with PYC at 10, 30, 100 mg/mL and analyzed daily. Significant differences relative to PYC 0 mg/mL treatment at day3 are indicated using P-values. (B) SK-L cells were infected with diluted vCSFV GPE−/HiBiT at a MOI = 0.01 in 96-well plates and incubated at 37 °C for 3 days. Virus growth was evaluated using the luciferase assay as described in the “Materials and methods”. Virus titers were calculated and expressed as TCID50 per mL.
Figure 5Silencing of target protein expression by siRNA. The effects of siRNA targeting against PKD1L3 and USP31 were examined using immunoblot analysis. Expression of the (A) PKD1L3 protein (~ 234 KDa, 150 KDa) and (B) USP31protein (~ 147 KDa) was evaluated (indicated by arrows). An anti-actin antibody was used as a loading control. Protein molecular weight markers (ThermoFisher Co.) are also shown. Original gel image is show in Supplementary Information.
Figure 6Effects of siRNA silencing of PKD1L3 and USP31 on CSFV-IRES activity. siRNAs targeting PKD1L3 and USP31 were reverse transfected into pCI5 and pCI5-1 cells using Lipofectamine RNAiMAX and incubated for 72 h. Firefly (CSFV-IRES activity) and Renilla (cap-dependent translation) luciferase activities were analyzed. (A) To evaluate IRES-mediated translational activity, the ratios of IRES-mediated translation vs. cap-dependent translation and vs. translation in untreated cells were calculated. Bars and vertical bars indicate the mean values of the triplicate samples and S.D, respectively. The Student’s t-test was performed to calculate P-values to compare control siRNA-treated cells and cells transfected with PKD1L3 and USP31 siRNA. *P = 0.022, #P = 0.012, +P = 0.013, @P = 0.01 (B) Cell viability was measured using WST assays by determining the OD450 and the ratios to the values for untreated cells. The experiments were performed in triplicate, and error bars indicate S.D.